SEED Therapeutics is an innovative biotech company focusing on harnessing and engineering “molecular glues” and targeted protein degradation (TPD) to attack previously undruggable targets. Backed by a comprehensive intellectual property portfolio, SEED Therapeutics' mission is to positively impact human health by creating novel protein degradation therapeutics to treat various severe diseases that currently have limited treatment options for patients and their families. Through ongoing collaborations with world-leading academic experts in the field, SEED Therapeutics is developing a growing pipeline of novel drug candidates on a path to potential clinical and commercial success. SEED has an initial R&D collaboration and investment from Eli Lilly. With today’s announcement, SEED’s Board of Directors is composed of SEED Chairman, CEO and Co-Founder Dr. Lan Huang, PhD, an ubiquitin ligase expert, biotech entrepreneur, and Chairman, CEO and Co-Founder of BeyondSpring; Dr. James Tonra, PhD, seasoned translational science leader and SEED President and Chief Scientific Officer; Dr. Linus Lin, PhD, drug discovery and development expert and global head of Eli Lilly Chorus; Jackson Tai, corporate governance, finance, and risk expert and recently retired Eli Lilly director; and Ko-Yung Tung, eminent international lawyer, cross-border strategic advisor, and former World Bank General Counsel. Learn more by visiting https://seedtherapeutics.com/. BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focusing on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform for novel drug development in oncology, neurodegeneration, and virology. Learn more by visiting https://beyondspringpharma.com , and follow us on LinkedIn and Twitter .